Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)

NCT05938920 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

71

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Pulmonary Fibrosis (IPF)

Interventions

DRUG: INS018_055
DRUG: Placebo

Sponsor

InSilico Medicine Hong Kong Limited